[EN] THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS [FR] THIÉNO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES ET ANALOGUES COMME MODULATEUR DE SIRTUINE
[EN] THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS<br/>[FR] THIÉNO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES ET ANALOGUES COMME MODULATEUR DE SIRTUINE
申请人:GLAXOSMITHKLINE LLC
公开号:WO2014138562A1
公开(公告)日:2014-09-12
Provided herein are novel substituted thieno[3,2-d]pyrimidine-6-carboxamide sirtuin inhibitors and methods of use thereof. The sirtuin inhibitors may be used for inhibiting a sirtuin-mediated biological process, and, e.g. for treating and/or preventing diseases and disorders including, but not limited to cancer, neurodegenerative disease and inflammation. Also provided herein are pharmaceutical compositions comprising these sirtuin inhibitors and compositions comprising a sirtuin inhibitor in combination with another therapeutic agent.
Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives
作者:Roger J. Gillespie、David R. Adams、David Bebbington、Karen Benwell、Ian A. Cliffe、Claire E. Dawson、Colin T. Dourish、Allan Fletcher、Suneel Gaur、Paul R. Giles、Allan M. Jordan、Antony R. Knight、Lars J.S. Knutsen、Anthony Lawrence、Joanne Lerpiniere、Anil Misra、Richard H.P. Porter、Robert M. Pratt、Robin Shepherd、Rebecca Upton、Simon E. Ward、Scott M. Weiss、Douglas S. Williamson
DOI:10.1016/j.bmcl.2008.03.075
日期:2008.5
The (-)-(11R,2'S)-enantiomer of the antimalarial drug mefloquine has been found to be a reasonably potent and moderately selective adenosine A(2A) receptor antagonist. Further investigation of this compound has led to the discovery of a series of keto-aryl thieno[3,2-d]pyrimidine derivatives, which are potent and selective antagonists of the adenosine A(2A) receptor. These derivatives show selectivity
THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS
申请人:GLAXOSMITHKLINE LLC
公开号:US20160002273A1
公开(公告)日:2016-01-07
Provided herein are novel substituted thieno[3,2-d]pyrimidine-6-carboxamide sirtuin inhibitors and methods of use thereof. The sirtuin inhibitors may be used for inhibiting a sirtuin-mediated biological process, and, e.g. for treating and/or preventing diseases and disorders including, but not limited to cancer, neurodegenerative disease and inflammation. Also provided herein are pharmaceutical compositions comprising these sirtuin inhibitors and compositions comprising a sirtuin inhibitor in combination with another therapeutic agent.